DAPA-HF Committees and Investigators

How do SGLT2 inhibitors reduce cardiovascular and renal risk in people with type 2 diabetes?

SGLT2 inhibitors reduce cardiovascular and renal risk in type 2 diabetes through a combination of renal hemodynamic effects, systemic metabolic shifts, and direct cardiac and vascular actions that go ...